4
MARKET OVERVIEW
Presents a concise view of industry direction, strategic priorities, and key indicators influencing market momentum.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNTIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Summarizes the competitive environment, macro signals, and segment-level movements driving market outcomes.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN THE NORTH AMERICA VACCINES MARKET
5.5.1
AVERAGE SELLING PRICE TREND OF VACCINES, BY KEY PLAYER, 2023–2025
5.5.2
AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION, 2023–2025
5.5.3
AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2021–2023
5.6.1
IMPORT SCENARIO (HS CODE 300220)
5.6.2
EXPORT SCENARIO (HS CODE 300220)
5.7
KEY CONFERENCES AND EVENTS, 2025–2026
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9
INVESTMENT AND FUNDING SCENARIO
5.9.1
VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
5.10
IMPACT OF 2025 US TARIFF – NORTH AMERICA VACCINES MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRIES
5.10.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
RECOMBINANT TECHNOLOGY
6.1.2
CONJUGATION TECHNOLOGY
6.1.3
VIRAL VECTOR TECHNOLOGY
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
ENCAPSULATION & DELIVERY TECHNOLOGY
6.2.2
AUTOMATION & CONTROL
6.3
ADJACENT TECHNOLOGIES
6.3.1
SINGLE-USE TECHNOLOGY
6.3.2
CELL LINE DEVELOPMENT
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.7
IMPACT OF AI/GEN AI ON NORTH AMERICA VACCINES MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
CASE STUDIES OF AI IMPLEMENTATION IN THE NORTH AMERICA VACCINES MARKET
6.7.3
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE NORTH AMERICA VACCINES MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.3
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
NORTH AMERICA VACCINES MARKET, BY DISEASE INDICATION
Market Size, Volume & Forecast – USD Million
9.6
MENINGOCOCCAL DISEASE
9.16
OTHER DISEASE INDICATIONS
10
NORTH AMERICA VACCINES MARKET, BY TECHNOLOGY
Market Size, Volume & Forecast – USD Million
10.2
VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY
10.2.1
CONJUGATE VACCINES
10.2.2
RECOMBINANT VACCINES
10.2.3
INACTIVATED & SUBUNIT VACCINES
10.2.4
LIVE ATTENUATED VACCINES
10.3
COVID-19 VACCINES MARKET, BY TECHNOLOGY
10.3.2
VIRAL VECTOR VACCINES
10.3.3
OTHER COVID-19 VACCINES
11
NORTH AMERICA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE
Market Size, Volume & Forecast – USD Million
11.2
MULTIVALENT VACCINES
12
NORTH AMERICA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION
Market Size, Volume & Forecast – USD Million
12.2
INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
12.4
OTHER ROUTES OF ADMINISTRATION
13
NORTH AMERICA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER
Market Size, Volume & Forecast – USD Million
14
NORTH AMERICA VACCINES MARKET, BY REGION, 2023-2030 (USD MILLION)
14.2.8
MACROECONOMIC OUTLOOK OF NORTH AMERICA
15.2
KEY PLAYERS STRATEGY/ RIGHT TO WIN
15.3
REVENUE ANALYSIS, 2022-2024
15.4
MARKET SHARE ANALYSIS,
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
15.5.5.1
COMPANY FOOTPRINT
15.5.5.2
REGION FOOTPRINT
15.5.5.3
TECHNOLOGY FOOTPRINT
15.5.5.5
ROUTE OF ADMINISTRATION FOOTPRINT
16.6
COMPANY EVALUATION MATRIX: START-UPS/SMES,
16.6.1
PROGRESSIVE COMPANIES
16.6.2
RESPONSIVE COMPANIES
16.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
16.6.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
16.6.5.2
COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
16.7
COMPETITIVE SCENARIO
16.7.3
OTHER DEVELOPMENTS
16.8
BRAND/ PRODUCT COMPARATIVE ANALYSIS
16.9
VALUATION AND FINANCIAL METRICS
17.1.3
MERCK & CO., INC (US)
17.1.4
JOHNSON & JOHNSON SERVICES, INC (US)
17.1.8
NOVAVAX, INC. (US)
18.1.1.1
KEY SOURCES OF SECONDARY DATA
18.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
18.1.2.1
BREAKDOWN OF PRIMARY INTERVIEWS
18.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
18.2
MARKET SIZE ESTIMATION
18.2.1
NORTH AMERICA VACCINES MARKET SIZE ESTIMATION
18.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
18.2.1.2
MNM REPOSITORY ANALYSIS
18.2.1.3
SECONDARY ANALYSIS
18.2.1.4
PRIMARY RESEARCH
18.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
17.3
MARKET GROWTH RATE PROJECTIONS
17.6
RESEARCH ASSUMPTIONS
17.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
19.2
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
AVAILABLE CUSTOMIZATIONS
Growth opportunities and latent adjacency in North America Vaccines Market